City
Epaper

J&K sees 415 new Covid cases, 745 recoveries

By IANS | Updated: June 27, 2021 19:50 IST

Srinagar, June 27 Recoveries continued to outnumber new Covid cases in J&K on Sunday as 745 patients recovered ...

Open in App

Srinagar, June 27 Recoveries continued to outnumber new Covid cases in J&K on Sunday as 745 patients recovered while 415 new cases and eight deaths were reported during the last 24 hours.

Officials said 171 cases and four deaths were reported from the Jammu division and 244 cases and four deaths from the Kashmir division.

As many as 29 cases of black fungus have also been reported so far.

So far, 314,731 people have been infected with coronavirus in J&K, out of which 305,135 have recovered, while 4,304 have succumbed.

There are 5,292 active cases, out of which 2109 are from the Jammu division and 3,183 are from the Kashmir division.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalUkraine's Zelensky can end war with Russia 'almost immediately': Trump

LifestyleToday's Horoscope, August 18, 2025: Check Your Zodiac Signs Predictions, Lucky Numbers and Colours

InternationalChinese Foreign Minister Wang Yi to arrive in India today for key talks with EAM Jaishankar, NSA Doval amid Trump tariffs

NationalChinese Foreign Minister Wang Yi to arrive in India today for key talks with EAM Jaishankar, NSA Doval amid Trump tariffs

InternationalHurricane Erin Weakens to Category 3: State of Emergency and Mandatory Evacuation Issued; What We Know So Far

Health Realted Stories

HealthBangladesh: One more person dies of dengue, 2025 toll rises to 105

HealthPrevention, not just medication, key to tackling obesity and diabetes: Jitendra Singh

HealthAyush seminar to boost ayurveda‑based paediatric healthcare

HealthIIT Kharagpur launches healthcare and technology school to train youth as health professionals

HealthNovel live type 1, 3 oral polio vaccines show promise in phase 1 trial